Abvx

**Abivax (ABVX) is a clinical-stage biotechnology company with a focus on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases.** Here's an analysis of the company's recent performance and prospects: 1. **Technical Analysis Indicators**: - **Closing Price and Resistance/Support Levels**: On July 29, 2025, ABVX closed at $69.8, with resistance at $8.57 and support at $5.88. - **MACD, RSI, and KDJ**: The MACD is at 13.67, RSI is at 93.01, and KDJ is at 96.32. These indicators suggest that the stock may be overbought, which could lead to a potential pullback. - **Moving Averages**: The 5-day moving average is $68.24, the 10-day is $39.15, and the 20-day is $23.66. The stock is trading above these averages, indicating a short-term uptrend. - **Net Fund Flow**: There was a net fund flow of $3.83 million, with a block order flow of $3.15 million. Positive fund flows indicate investor confidence and potential growth. |code|Ticker|Name|Date|Support Level|Resistance Level|market_code| |---|---|---|---|---|---|---| |ABVX|ABVX.O|Abivax|20250729|5.8825|8.5744|185| |code|Ticker|Name|Date|Boll|RSI|KDJ|MACD|market_code| |---|---|---|---|---|---|---|---|---| |ABVX|ABVX.O|Abivax|20250729|23.6585|93.0062|96.3157|13.6703|185| |code|Ticker|Name|Date|Net Fund Flow|Net Fund Flow (Block Order)|market_code| |---|---|---|---|---|---|---| |ABVX|ABVX.O|Abivax|20250106|-140644.2689|-144894.6888|185| |ABVX|ABVX.O|Abivax|20250107|-108074.3762|-90685.1528|185| |ABVX|ABVX.O|Abivax|20250108|-56243.7738|-18646.2371|185| |ABVX|ABVX.O|Abivax|20250110|-105101.9564|-70511.5532|185| |ABVX|ABVX.O|Abivax|20250113|-122271.0788|1194.4558|185| |ABVX|ABVX.O|Abivax|20250114|-68617.4288|-59841.944|185| |ABVX|ABVX.O|Abivax|20250115|-8152.7593|-1607.9549|185| |ABVX|ABVX.O|Abivax|20250116|6828.6963|-4125.05|185| |ABVX|ABVX.O|Abivax|20250117|-16383.8647|-21935.4563|185| |ABVX|ABVX.O|Abivax|20250121|49898.2068|74375.775|185| |code|Ticker|Name|Date|Moving Average|market_code| |---|---|---|---|---|---| |ABVX|ABVX.O|Abivax|20250729|68.2440|185| 2. **Valuation Metrics**: - **P/E Ratio**: The P/E ratio is -25.61, which is negative and suggests that the company is not profitable as per the current earnings. - **P/S Ratio**: The P/S ratio is 388.09, indicating that the market is currently valuing the company at a significant premium to its sales. - **P/B Ratio**: The P/B ratio is -721.61, which is negative and suggests that the company may be unprofitable or has significant losses. |code|Ticker|Name|Date|P/E(TTM)|P/S|Price to Book Ratio|market_code| |---|---|---|---|---|---|---|---| |ABVX|ABVX.O|Abivax|20240730|-4.554341||3.432775783682514|185| |ABVX|ABVX.O|Abivax|20240731|-4.546641||3.4269722743271753|185| |ABVX|ABVX.O|Abivax|20240801|-4.527392||3.41246350093883|185| |ABVX|ABVX.O|Abivax|20240802|-4.608238||3.4734003491698804|185| |ABVX|ABVX.O|Abivax|20240805|-4.254055||3.206438918824326|185| |ABVX|ABVX.O|Abivax|20240806|-4.207857||3.1716178626922966|185| |ABVX|ABVX.O|Abivax|20240807|-4.334901||3.2673757670553765|185| |ABVX|ABVX.O|Abivax|20240808|-4.323351||3.258670503022369|185| |ABVX|ABVX.O|Abivax|20240809|-4.307952||3.247063484311693|185| |ABVX|ABVX.O|Abivax|20240812|-4.230956||3.1890283907583115|185| 3. **Recent News and Analyst Opinions**: - **Public Offering**: Abivax successfully closed a $747.5 million public offering, which includes the full exercise of the underwriters' option. This significant capital raise will fund operations through the fourth quarter of 2027. - **Phase III Data**: The company announced positive Phase III trial results for its lead pipeline candidate, obefazimod, in treating moderately to severely active ulcerative colitis. This data led to a dramatic increase in stock price, with Abivax announcing a $400 million public offering. - **Analyst Ratings**: Oddo BHF maintained an outperform recommendation with a target price raised from €24 to €88. LifeSci Capital increased the price target from $45 to $101 following the positive Phase III results. 4. **Market Sentiment and Future Prospects**: - **Market Sentiment**: The stock has seen a significant surge due to positive clinical trial results and investor confidence in the company's pipeline. - **Future Prospects**: Abivax is positioned to pursue a New Drug Application (NDA) for obefazimod in the second half of 2026, with plans to launch the drug in the second half of 2027. The company's financial position has been significantly strengthened by the recent capital raise, which will support its operations during this critical clinical development period. In conclusion, Abivax (ABVX) is a biotechnology company with a strong research pipeline and recent positive clinical trial results. The company's stock has seen a significant increase in value due to these results and successful capital raises. However, the negative P/E and P/B ratios indicate that the company is currently unprofitable. Investors should monitor the company's progress in regulatory filings and commercialization of its lead drug candidate.